Table 4.

Summary of efficacy outcomes (safety analysis set)

	Patients with malignant lymphoma (N = 51)
Bone-marrow suppression, n (%) [95% CI]	51 (100.0) [93.0, 100.0]
Neutrophil engraftmenta, n (%) [95% CI]	47 (92.2) [81.1, 97.8]
Time to engraftment (days), median (min, max)	11.0 (8, 17)
Evaluable subjects at day 100 post-HSCT, n	48
Survival at day 100, n (%) [95% CI]	48 (100.0) [–, –]

^aDefined as the proportion of patients with a neutrophil count ≥ 500/mm³ for 3 consecutive days after bone-marrow suppression and HSCT

CI confidence interval, HSCT hematopoietic stem cell transplantation